Skip to main content
. 2020 Jun 12;11:394. doi: 10.3389/fneur.2020.00394

Table 1.

Demographic, molecular and clinical characteristics of the cohort of study.

Count (%) Mean (SD) n
Male 35 (57.4%) 61
Age at disease onset 32.34 (15.28) 61
Age at examination 47.20 (13.85) 61
Disease duration 14.85 (9.37) 61
BMI 24.21 (4.78) 61
    BMI ≥ 30 8 (13.1%)
(CTG)n 466.17 (269.32) 53
MIRS score 2.89 (0.84) 61
Comorbidities 61
    Hypertension 11 (18%)
    Steatosis 21 (34.4%)
    Diabetes type II 6 (9.8%)
    Cholelithiasis 19 (31.1%)
    Cholecistectomy 12 (19.7%)
    Hepatitis C 1 (1.6%)
GI symptoms 44 (72%) 61
    GERD 24 (39.3%)
    GERD (GSRS score) 2.16 (1.69)
    Abdominal discomfort 27 (44.3%)
    Abdominal discomfort (GSRS score) 2.31 (1.80)
    Abdominal pain 20 (32.8%)
    Abdominal pain (GSRS score) 1.95 (1.62)
    Constipation 28 (45.9%)
    Constipation (GSRS score) 2.47 (1.83)
    Diarrhea 24 (39.3%)
    Diarrhea (GSRS score) 1.89 (1.38)
    Constipation/Diarrhea 15 (24.6%)
Medications 61
    Mexiletine 14 (23%)
    Anti-hypertensives 11 (18%)
    Aspirin 11 (18%)
    Insulin 3 (4.9%)
    Metformin 5 (8.2%)
    Ursodeoxycholic acid 5 (8.2%)
    Hypolipidemic drugs (ezetimibe or omega 3-fatty acids) 14 (23%)
    Anti-constipation medicines 7 (11.5%)
    PPIs 21 (34.4%)
    Probiotics 4 (6.6%)
    Vitamine D supplements 30 (49.2%)
Blood tests
    Glucose 91.8 (26.69) 61
    Impaired glucose tolerance (>110 UI/l) 7 (11.5%) 61
    GPT 38.46 (24.77) 57
    GPT out of range (>45 UI/l) 17 (29.82%) 57
    GGT 88.22 (101.71) 60
    GGT out of range (>36 UI/l) 39 (65%) 60
    Alkaline phosphatase 80.81 (31.66) 54
    Amylase 58.53 (29.97) 45
    Total cholesterol 188.22 (40.62) 59
    Hypercholesterolemia (>200 mg/dl) 21 (35.59%) 59
    Triglycerides 152.41 (71.14) 59
    Vitamine D 24.75 (13.05) 48
    Vitamine D below the normal range (<30 UI/l) 32 (66.67%) 48
    Creatinine 0.75 (0.25) 59
    Erythrocyte Sedimentation Rate 14.39 (17.33) 46
Intestinal permeability (IP)
    Total IP 6.71 (4.57) 57
    Altered 52 (91.22%) 57

SD, standard deviation; BMI, Body Mass Index; MIRS, muscular impairment rating scale; GI, gastrointestinal; GERD, gastroesophageal reflux disease; GSRS, Gastrointestinal Symptom Rating Scale; NAFLD, non-alcoholic fatty liver disease; PPI, proton pump inhibitor; IP, intestinal permeability.